Steel and Aluminum Tariffs: Recovery and Risk Reduction for Federal Contractors
Client Alert | less than 1 min read | 03.07.18
On March 1, the President announced his intention to impose tariffs of 25 percent on all imported steel and 10 percent on all imported aluminum. When finalized, the tariffs could increase costs of performance and restrict available supply for contractors across a range of industries. Federal contractors who manufacture or use products containing steel or aluminum should examine their existing contracts, as many may include risk-shifting provisions with opportunities for recovery through price adjustments or relief through schedule adjustments. Federal contractors also should consider re-evaluating pricing of offers and revising standard contract terms. Click here to read the full post on our Government Contracts blog.
Contacts
Insights
Client Alert | 4 min read | 04.10.25
Hikma and Amici Curiae Ask Supreme Court to Revisit Induced Infringement by Generic “Skinny Labels”
In Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., C.A. No. 20-1630 (D. Del.), brand manufacturer Amarin brought an induced infringement claim against Hikma’s generic icosapent ethyl product, which lists Amarin’s Vascepa® as the reference listed drug. Vascepa was originally approved by the U.S. Food and Drug Administration (“FDA”) to treat severe hypertriglyceridemia, and later, Amarin obtained patents and approval for Vascepa as a treatment to reduce cardiovascular risk in certain patient populations. Hikma’s Abbreviated New Drug Application (“ANDA”) for generic icosapent ethyl included a Section viii statement that Hikma was not seeking approval for the patented cardiovascular indication along with a “skinny label” that included only the indication for severe hypertriglyceridemia.
Client Alert | 1 min read | 04.09.25
Client Alert | 12 min read | 04.09.25
Client Alert | 4 min read | 04.07.25
